Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.

Shore N, Tutrone R, Efros M, Bidair M, Wachs B, Kalota S, Freedman S, Bailen J, Levin R, Richardson S, Kaminetsky J, Snyder J, Shepard B, Goldberg K, Hay A, Gange S, Grunberger I.

World J Urol. 2018 May;36(5):801-809. doi: 10.1007/s00345-018-2185-y. Epub 2018 Jan 29.

2.

EFFICACY AND SAFETY OF A NEW TOPICAL TESTOSTERONE REPLACEMENT GEL THERAPY FOR THE TREATMENT OF MALE HYPOGONADISM.

Cunningham G, Belkoff L, Brock G, Efros M, Gittelman M, Carrara D, Neijber A, Ando M, Mitchel J.

Endocr Pract. 2017 May;23(5):557-565. doi: 10.4158/EP161665.OR. Epub 2017 Feb 22.

PMID:
28225313
3.

The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies.

Efros M, Carrara D, Neijber A.

Andrologia. 2016 Aug;48(6):637-45. doi: 10.1111/and.12493. Epub 2015 Nov 24.

PMID:
26598279
4.

Effect of tadalafil once daily on prostate blood flow and perfusion in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, double-blind, multicenter, placebo-controlled trial.

Pinggera GM, Frauscher F, Paduch DA, Bolyakov A, Efros M, Kaminetsky J, Da Pozzo L, Esler A, Cox D.

Urology. 2014 Aug;84(2):412-9. doi: 10.1016/j.urology.2014.02.063. Epub 2014 Jun 14.

PMID:
24938580
5.

A green and black tea extract benefits urological health in men with lower urinary tract symptoms.

Katz A, Efros M, Kaminetsky J, Herrlinger K, Chirouzes D, Ceddia M.

Ther Adv Urol. 2014 Jun;6(3):89-96. doi: 10.1177/1756287214526924.

6.

A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia.

McVary KT, Roehrborn CG, Chartier-Kastler E, Efros M, Bugarin D, Chen R, Patel A, Haag-Molkenteller C.

J Urol. 2014 Jul;192(1):150-6. doi: 10.1016/j.juro.2014.02.004. Epub 2014 Feb 7. Erratum in: J Urol. 2015 Jan;193(1):374.

PMID:
24508634
7.

PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study.

Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, Efros M, Bidair M, Ward JF.

J Urol. 2013 Jul;190(1):64-9. doi: 10.1016/j.juro.2013.02.018. Epub 2013 Feb 14.

PMID:
23416644
8.

A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.

Paller CJ, Ye X, Wozniak PJ, Gillespie BK, Sieber PR, Greengold RH, Stockton BR, Hertzman BL, Efros MD, Roper RP, Liker HR, Carducci MA.

Prostate Cancer Prostatic Dis. 2013 Mar;16(1):50-5. doi: 10.1038/pcan.2012.20. Epub 2012 Jun 12.

9.

A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.

Messing E, Gee JR, Saltzstein DR, Kim K, diSant'Agnese A, Kolesar J, Harris L, Faerber A, Havighurst T, Young JM, Efros M, Getzenberg RH, Wheeler MA, Tangrea J, Parnes H, House M, Busby JE, Hohl R, Bailey H.

Cancer Prev Res (Phila). 2012 Apr;5(4):621-30. doi: 10.1158/1940-6207.CAPR-11-0455. Epub 2012 Jan 31.

10.

Novel concentrated cranberry liquid blend, UTI-STAT with Proantinox, might help prevent recurrent urinary tract infections in women.

Efros M, Bromberg W, Cossu L, Nakeleski E, Katz AE.

Urology. 2010 Oct;76(4):841-5. doi: 10.1016/j.urology.2010.01.068.

PMID:
20399486
11.

Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes.

Norkina O, Dolganiuc A, Catalano D, Kodys K, Mandrekar P, Syed A, Efros M, Szabo G.

Alcohol Clin Exp Res. 2008 Sep;32(9):1565-73. doi: 10.1111/j.1530-0277.2008.00726.x. Epub 2008 Jul 9.

12.

Urologic complications of high-dose chemotherapy and bone marrow transplantation.

Efros MD, Ahmed T, Coombe N, Choudhury MS.

Urology. 1994 Mar;43(3):355-60.

PMID:
8134990
13.

Interferons and interleukins in metastatic renal cell carcinoma.

Choudhury M, Efros M, Mittelman A.

Urology. 1993 Jan;41(1 Suppl):67-72. Review.

PMID:
7678365
14.

Unusual primary prostatic malignancies.

Efros MD, Fischer J, Mallouh C, Choudhury M, Georgsson S.

Urology. 1992 May;39(5):407-10.

PMID:
1315994
15.
16.

Pharmacology and toxicology of dysprosium, holmium, and erbium chlorides.

Haley TJ, Koste L, Komesu N, Efros M, Upham HC.

Toxicol Appl Pharmacol. 1966 Jan;8(1):37-43. No abstract available.

PMID:
5921895
17.

INFLUENCE OF PHYSOSTIGMINE AND NEOSTIGMINE ON THE RESPONSES OF GOLDFISH INTESTINE TO ACETYLCHOLINE.

HALEY TJ, COLVIN G, EFROS M.

J Pharm Sci. 1964 Dec;53:1530-1. No abstract available.

PMID:
14255139
18.

PHARMACOLOGY AND TOXICOLOGY OF LUTETIUM CHLORIDE.

HALEY TJ, KOMESU N, EFROS M, KOSTE L, UPHAM HC.

J Pharm Sci. 1964 Oct;53:1186-8. No abstract available.

PMID:
14249433
19.

PHARMACOLOGY AND TOXICOLOGY OF PRASEODYMIUM AND NEODYMIUM CHLORIDES.

HALEY TJ, KOMESU N, EFROS M, KOSTE L, UPHAM HC.

Toxicol Appl Pharmacol. 1964 Sep;6:614-20. No abstract available.

PMID:
14217003

Supplemental Content

Support Center